Mualliflar

  • Xusanbayev X.Sh., Yusupov A.F.

##semicolon##

proliferativ diabetik retinopatiya, asoratlar, vitrektomiya, panretinal lazer koagulyatsiyasi, funksional natijalara

##submission.citations##

Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564.

Klein R, Klein BE, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 1984; 102:520–526.

Saaddine JB, Honeycutt AA, Narayan KM, et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes. Arch Ophthalmol. 2008; 126:1740–1747.

Charles S. Vitreous microsurgery. 5th ed. Wolters Kluwer; 2020.

Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs ranibizumab for proliferative diabetic retinopathy. JAMA. 2015; 314:213 7–2146.

ETDRS Research Group. Photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1991; 98:766–785.

Comyn O, et al. Visual function after pan-retinal photocoagulation: systematic review. Eye. 20 14; 28:720–728.

Wang ZY, Zhao KK, Li B, et al. Four-port bimanual 25-gauge vitrectomy for severe proliferative diabetic retinopathy. Int J Ophthalmol. 2016; 9:1130–1134.

DRCR.net. Five-year outcomes of aflibercept, bevacizumab, or ranibizumab for PDR. Ophthalmology. 2020; 127:1201–1212.

Fallico M, et al. Intravitreal anti-VEGF vs PRP for PDR: network meta-analysis. Acta Ophthalmol. 2021;99: e267–e275.